FIXED DOSE COMBINATION OF OFLOXACIN AND ORNIDAZOLE WITH CROSSSENSITIVITY TO METRONIDAZOLE INDUCED FIXED DRUG ERUPTION

Abstract

Fixed drug eruption (FDE) is a recurrent, clearly dened lesion that consistently develops at the same location after taking the offending substance [1]. The lips, face, hands, feet, and genitalia are the typical sites for the lesions [2]. It can be identied by its benign character, short latency, and recurrence at the same places on rechallenge. Resting FDE lesions contain CD8+ T-cells with a memory characteristic that were situated at the dermal-epidermal junction and are silent until the drug is re-challenged after healing. Most FDE cases have excellent prognoses and are selflimiting. After the acute incident, post-inammatory hyperpigmentation can be noticeable and last for several months. Ooxacin is a uoroquinolone of second-generation that prevents the synthesis of microbial DNA. Ornidazole is a 5- nitroimidazole with antibacterial and antiparasitic properties. Metronidazole has broad-spectrum cidal action against anaerobic protozoa. It is frequently given in combination with other antimicrobial agents to treat polymicrobial infections with aerobic and anaerobic bacteria. The most frequent combination causing xed drug eruption among the anti-microbial FDC is uoroquinolones + nitroimidazole. We report a case of ornidazole with cross-sensitivity to metronidazole-induced xed drug eruption in an adult male of thirties treated for diarrhea.